Patents by Inventor Kazuhiro Kudou

Kazuhiro Kudou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170247342
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro KUDOU, Masato NAGATSUKA
  • Patent number: 9676703
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: June 13, 2017
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro Kudou, Masato Nagatsuka
  • Publication number: 20160200690
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Application
    Filed: August 8, 2014
    Publication date: July 14, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro KUDOU, Masato NAGATSUKA
  • Patent number: 9029572
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: May 12, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Publication number: 20140371459
    Abstract: Provided is a method for producing a compound represented by formula (7) or a salt thereof: the method comprising the steps of: removing a R1 group and a R2 group from a compound represented by formula (5) or a salt thereof: and reacting the compound (in which R1 and R2 in formula (5) are hydrogen atoms) obtained in the removing step or a salt thereof with a compound represented by formula (d): or a salt thereof in the presence of a base. The method is a method for producing a 1,2-dihydroquinoline derivative having glucocorticoid receptor binding activity or a salt thereof. This method does not require a purification step by column chromatography and is suitable for industrial production.
    Type: Application
    Filed: January 21, 2013
    Publication date: December 18, 2014
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., KYOWA HAKKO BIO CO., LTD.
    Inventors: Noriyoshi Yamamoto, Atsushi Ohno, Kazuhiro Kudou, Masakazu Ban, Takashi Mimura, Takashi Ohtani
  • Publication number: 20140296540
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Kazuhiro KUDOU, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Patent number: 8802869
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: August 12, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Publication number: 20130310576
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Application
    Filed: February 8, 2012
    Publication date: November 21, 2013
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Patent number: 8193237
    Abstract: Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKK? and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKK?. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: June 5, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Enomoto, Kenji Kawashima, Kazuhiro Kudou, Minoru Yamamoto, Masaaki Murai, Takaaki Inaba, Noriko Ishizaka
  • Patent number: 7977371
    Abstract: Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: July 12, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Kawashima, Hiroshi Enomoto, Noriko Ishizaka, Minoru Yamamoto, Kazuhiro Kudou, Masaaki Murai, Takaaki Inaba, Kazuyoshi Okamoto
  • Publication number: 20100099675
    Abstract: Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease.
    Type: Application
    Filed: February 26, 2008
    Publication date: April 22, 2010
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Hiroshi Enomoto, Noriko Ishizaka, Minoru Yamamoto, Kazuhiro Kudou, Masaaki Murai, Takaaki Inaba, Kazuyoshi Okamoto
  • Publication number: 20100041628
    Abstract: Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKK? and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKK?. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.
    Type: Application
    Filed: January 15, 2008
    Publication date: February 18, 2010
    Inventors: Hiroshi Enomoto, Kenji Kawashima, Kazuhiro Kudou, Minoru Yamamoto, Masaaki Murai, Takaaki Inaba, Noriko Ishizaka